Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkv428PMID 26702923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gentamicin and Renal Function: Lessons From 15 Years' Experience of a Pharmacokinetic Service for Extended Interval Dosing of Gentamicin

  2015cited by this paper
• Stochastic Process Pharmacodynamics: Dose Timing in Neonatal Gentamicin Therapy as an Example

  2015cited by this paper
• Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.

  2015cited by this paper
• Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics

  2014cited by this paper
• Diffuse Interstitial Brain Edema in Patients With End-Stage Renal Disease Undergoing Hemodialysis: A Tract-Based Spatial Statistics Study

  2014cited by this paper
• Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.

  2014cited by this paper
• Population Pharmacokinetics of Gentamicin and Dosing Optimization for Infants

  2014cited by this paper
• Pharmacometrics in Bacterial Infections

  2014cited by this paper
• The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin.

  2013cited by this paper
• Infection and hemodialysis access: an updated review.

  2013cited by this paper
• Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization

  2011cited by this paper
• Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants

  2011cited by this paper
• Editorial: Aminoglycosides in Hemodialysis Patients: Is the Current Practice of Post Dialysis Dosing Appropriate?

  2009cited by this paper
• Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing.

  2008cited by this paper
• Identification of a new gene PA5017 involved in flagella-mediated motility, chemotaxis and biofilm formation in Pseudomonas aeruginosa.

  2007cited by this paper
• Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains.

  2007cited by this paper
• Comparative Pharmacodynamics of Gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa

  2006cited by this paper
• Dosing of Gentamicin in Patients With End‐Stage Renal Disease Receiving Hemodialysis

  2006cited by this paper
• In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.

  2003cited by this paper
• AMINOGLYCOSIDE ANTIBIOTICS

  2003cited by this paper
• Population pharmacokinetics of gentamicin in patients with cancer.

  2002cited by this paper
• Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives

  1999cited by this paper
• Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review.

  1997cited by this paper
• Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality

  1997cited by this paper
• Gentamicin concentrations in human subcutaneous tissue

  1996cited by this paper
• A suggested approach to once-daily aminoglycoside dosing.

  1995cited by this paper
• Aminoglycosides--50 years on.

  1995cited by this paper
• The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological malignancy.

  1994cited by this paper
• Serum Protein Binding of the Aminoglycoside Antibiotics

  1972cited by this paper

• Polydopamine-Antibiotic Composite Coating for Antibiofilm Applications.

  2025cites this paper
• Safety and Tolerability of Antimicrobial Agents in the Older Patient

  2023cites this paper
• Pharmacometrics: The Already-Present Future of Precision Pharmacology

  2022cites this paper
• Pharmacokinetic/Pharmacodynamic Modeling and Application in Antibacterial and Antifungal Pharmacotherapy: A Narrative Review

  2022influential citation
• Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review

  2022cites this paper
• Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis

  2022cites this paper
• Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance

  2022cites this paper
• Gentamicin Administration in Dialysis Patients: Before or After Hemodialysis?

  2022cites this paper
• Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis

  2021cites this paper
• Preclinical evaluation of efficacy and pharmacokinetics of gentamicin containing extracellular‐matrix envelope

  2020cites this paper
• PK/PD Approaches

  2020cites this paper
• Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End‐Stage Renal Disease Patients Using Modeling and Simulation

  2020cites this paper
• Population pharmacokinetics of gentamicin in haemodialysis patients: modelling, simulations and recommendations

  2020cites this paper
• Anti-Infective Agents

  2019cites this paper
• Modeling in Pharmacometrics

  2019cites this paper
• A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.

  2019cites this paper
• A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa

  2018cites this paper
• Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients

  2017cites this paper
• Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy

  2017cites this paper
• Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms

  2017cites this paper
• Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.

  2017cites this paper
• Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae

  2016cites this paper
• Pharmacokinetic-Pharmacodynamic modeling and prediction of antibiotic effects

  2016cites this paper
• Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development

  2016cites this paper